Allergan defended the safety of its breast implants, but its shares fell 7.4 percent to $135.94 on Wednesday as some Wall Street analysts questioned whether the company would have to face any future product liability costs. France's National Agency for the Safety of Medicines & Health Products (ANSM) said late on Tuesday that it was recalling Allergan's Microcell and Biocell textured breast implants because its safety certification had not been renewed by another agency. Textured breast implants, which have a rough surface and are more commonly used in Europe than in the United States, have been linked to a rare type of cancer known as anaplastic large cell lymphoma.

https://news.yahoo.com/allergan-stops-sales-europe-breast-implants-linked-cancer-065007538--finance.html